NCT05922579View on ClinicalTrials.gov

A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

TerminatedOBSERVATIONAL
Enrollment

191

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
Neuroendocrine Tumors
Trial Locations (1)

2000

CAPPRE, Sydney

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY